MEFENAMIC ACID 250 MG + DROTAVERINE HYDROCHLORIDE 80 MG TABLETS are a combination solid oral formulation developed around two active pharmaceutical ingredients with different physicochemical characteristics. The formulation requires careful consideration of powder behavior, active-ingredient distribution, excipient compatibility, compression properties, and finished-tablet uniformity. For pharmaceutical companies developing combination products, this formulation can be incorporated into a professionally structured PCD Pharma Franchise portfolio with appropriate manufacturing controls and product documentation.
The development process starts with evaluation of both active ingredients and the selected pharmaceutical excipients. Since each component can demonstrate different particle characteristics, densities, and flow properties, the manufacturing process needs to be designed to minimize segregation and maintain consistent distribution throughout the blend.
The formulation development of Mefenamic Acid 250 MG + Drotaverine Hydrochloride 80 MG Tablets begins with assessment of the two active pharmaceutical ingredients individually and together. Their particle size, bulk density, moisture characteristics, flow behavior, and compatibility with proposed excipients can influence the final manufacturing strategy.
Excipients may include suitable diluents, binders, disintegrants, glidants, and lubricants depending on the selected formulation technology. Their quantities are established according to the required tablet weight, compression behavior, and physical characteristics of the finished dosage form.
Compatibility evaluation can be performed to assess potential interactions between the active ingredients and excipient system. This supports selection of a formulation that remains physically and chemically consistent during processing and storage.
For a combination tablet, maintaining a homogeneous distribution of both active ingredients is particularly important. The formulation-development process therefore considers the characteristics of each component rather than treating the combination as a single material.
Powder handling is a significant stage in the production of Mefenamic Acid 250 MG + Drotaverine Hydrochloride 80 MG Tablets. Differences in particle size and density between the two active ingredients and the excipients can influence blend behavior and segregation tendencies.
Depending on the material characteristics, particle-size adjustment, pre-blending, geometric dilution, lubrication, or granulation may be incorporated into the manufacturing process. The selected approach should provide suitable flow and compressibility while maintaining active-ingredient uniformity.
Blend samples may be collected from predetermined locations and evaluated according to established in-process procedures. Parameters such as bulk density, moisture content, flow properties, and blend uniformity can provide useful information about process consistency.
Controlled material transfer is also important after blending. Excessive movement, vibration, or unsuitable handling can potentially disturb a homogeneous powder mixture. Therefore, standardized transfer and hopper-management practices can contribute to maintaining blend consistency before compression.
Once the blend demonstrates suitable processing characteristics, compression parameters are established for the tablet. Machine speed, compression force, dwell time, tooling configuration, and fill depth can influence tablet weight, thickness, hardness, and overall mechanical strength.
During manufacturing, in-process checks may be performed at defined intervals. Tablet weight, dimensions, hardness, friability, appearance, and other physical parameters can be monitored to identify process variation.
The formulation may also be evaluated for disintegration and dissolution characteristics using appropriate laboratory methods. These tests help assess the consistency of the finished dosage form and provide useful information for formulation and process control.
If a coating system is used, coating parameters such as spray conditions, drying, weight gain, and surface uniformity can be controlled to achieve a consistent finished appearance. The final tablets should maintain their structural integrity through dedusting, inspection, packaging, and transportation.
Quality testing of Mefenamic Acid 250 MG + Drotaverine Hydrochloride 80 MG Tablets begins with controlled evaluation of incoming raw materials. Each material can be assessed against predefined specifications before being approved for production.
Finished-product testing may include identification and assay of the individual active ingredients, uniformity-related testing, dissolution, disintegration, friability, hardness, weight variation, and other applicable parameters. Because this is a dual-active formulation, analytical methods should be capable of distinguishing and accurately quantifying the respective ingredients.
In-process testing provides an additional layer of control by monitoring important manufacturing parameters before completion of the batch. Results are documented as part of the overall batch manufacturing and quality-control record.
Stability studies may subsequently be conducted under defined storage conditions. Samples can be assessed at predetermined intervals for chemical, physical, and performance characteristics to monitor product consistency throughout its proposed shelf life.
Packaging development for Mefenamic Acid 250 MG + Drotaverine Hydrochloride 80 MG Tablets considers both product protection and practical handling requirements. Blister strips, aluminium-based configurations, or other suitable pharmaceutical-grade packaging systems may be selected according to the formulation and stability requirements.
The packaging system should provide suitable protection against environmental factors while maintaining tablet integrity during transportation and storage. Container-closure or blister-sealing performance, material compatibility, and moisture-barrier characteristics may be evaluated during packaging development.
Before dispatch, finished packs can be inspected for tablet count, seal integrity, batch number, manufacturing and expiry details, labeling accuracy, and overall pack presentation. Proper coding and documentation also support traceability throughout the distribution chain.
For pharmaceutical businesses expanding their combination-product range, Mefenamic Acid 250 MG + Drotaverine Hydrochloride 80 MG Tablets can be integrated into a broader PCD Pharma Franchise portfolio through controlled formulation development, reproducible manufacturing, analytical testing, stability monitoring, and professional packaging. A systematic approach across these stages helps maintain consistent product quality and supports organized pharmaceutical portfolio development.
Mefenamic Acid 250mg + Drotaverine 80mg Tablets with formulation, manufacturing, quality testing, stability, packaging and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech